Elevance Health (ELV) Q2 2026 Earnings Call Transcript

Elevance Health reported Q2 adjusted diluted EPS of $7.45, beating internal projections, and raised full-year 2026 adjusted EPS guidance to at least $27 (from prior outlook) while projecting a 2027 target of at least 12% adjusted EPS growth off a re-established 2026 baseline of at least $26. Operating revenue rose to $49.8B (+0.8% YoY) as favorable Medicare Advantage and Individual ACA benefit expense performance offset lower health plan membership. The company expects Medicaid operating margin to be about -1.75% as a trough in 2026 but anticipates improvement in 2H 2026 supported by July 1 rate updates, and it is allocating $0.80/share of one-time non-recurring gains to accelerate medical cost management and digital/provider connectivity capabilities.

Analysis

The real signal is not the headline beat; it’s that ELV is re-underwriting its earnings base while shrinking low-return exposure. Management is effectively saying the portfolio can absorb Medicaid pressure, funding retooling, and still compound at a double-digit rate—so the market should start valuing the mix shift and cost-control engine, not just quarter-to-quarter medical loss ratio noise. That supports multiple expansion if investors believe the 2027 baseline is cleaner than the 2026 optics suggest.

The second-order winner is Carelon and the company’s contract retention in commercial/ACA, because tighter provider connectivity and faster authorization improve employer stickiness and reduce leakage to the big integrated peers. The loser set is Medicaid-heavy managed care where scale alone no longer protects returns; that dynamic can force more rational pricing or market exits across the cohort. Near term, the main risk is that utilization in Medicaid and specialty categories stays sticky enough to offset rate relief, which would keep the stock range-bound despite raised guidance.

Contrarian take: consensus may be underestimating how much of the “bad news” is already being surfaced now, especially the willingness to exit unproductive markets and reserve conservatively in ACA. The flip side is that investors may be overpaying for the 2027 growth narrative if the company has to keep buying down volatility with one-time investments. Falsifiers are simple: if Medicaid margin does not improve sequentially in 2H or if ACA reserve prudence proves excessive, the de-risking story breaks.

Key Decisions for Investors

• Long ELV vs short IHF for 1-3 months: buy the company with the clearer self-help and capital flexibility while fading the managed-care basket’s exposure to Medicaid noise; target 8-12% relative outperformance if ELV continues to de-risk.
• Buy ELV on pullbacks below the post-earnings gap support for a 6-12 month hold: the setup is better for patient capital than momentum chasing, with downside mainly tied to Medicaid trend surprises and upside from 2027 earnings re-rating.
• If available, use ELV bull call spreads 3-6 months out instead of outright stock: the asymmetry is better if the market stays skeptical through the next Medicaid update but rewards any evidence of sequential margin improvement.
• Set a watch-item alert for any revision to Medicaid rate timing or ACA risk-adjustment accruals: a negative reset would be the cleanest thesis breaker and likely the trigger for de-rating.